J&J considers selling wound care division

One Equity Partners is on a shopping binge, it appears. The company, which recently purchased Prodigy Health Group for $110 million, has made an undisclosed offer to buyout the wound care portion of J&J's Ethicon division, which had $270 million in sales last year.

If the deal goes through, J&J will hand over the keys to its manufacturing facility in Gargrave England, along with an assortment of dressings and wound care products, including a prescription gel for diabetic leg ulcers. Ethicon's full-time 600 employees and 200 contractors would become employees of One Equity as part of the deal. 

One Equity manages investments for JP Morgan Chase. The company gave J&J until August 22 to make a decision. Overall, Ethicon generated $3.5 billion in sales in 2007. The offer is irrevocable and unconditional. If J&J accepts, it will likely close this year. 

- get the story from the New York Times.
- read about the dealsat the DealBook blog

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.